HONG KONG, July 23, 2026
Ascletis Pharma Inc. has announced that new preclinical data for its investigational obesity therapy ASC36_35 fixed-dose combination (FDC) has been selected for a short oral discussion at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting, scheduled to take place in Milan, Italy, from September 28 to October 2, 2026. The presentation will highlight findings demonstrating that the once-monthly ASC36_35 co-formulation achieved superior weight loss compared with the eloralintide and tirzepatide combination in a diet-induced obese (DIO) animal model. The selection of the data for an oral presentation underscores the growing scientific interest in next-generation obesity therapeutics that combine multiple metabolic targets to improve efficacy while reducing dosing frequency. The investigational therapy integrates ASC36, an amylin receptor agonist, with ASC35, a GLP-1R/GIPR dual agonist, creating a potentially first-in-class triple-target approach for chronic weight management.
ASC36_35 Demonstrates Superior Preclinical Weight Loss
According to Ascletis, the ASC36_35 fixed-dose combination produced greater weight loss than the combination of eloralintide and tirzepatide in preclinical studies involving diet-induced obese (DIO) rats. The once-monthly injectable therapy combines complementary mechanisms targeting the amylin receptor, GLP-1 receptor, and GIP receptor, all of which have become important therapeutic targets in obesity management. By integrating these validated metabolic pathways into a single co-formulation, the investigational candidate aims to maximize weight reduction while improving patient convenience through monthly dosing. The company believes the encouraging preclinical findings support the potential for ASC36_35 to deliver clinically meaningful improvements in weight management and warrant continued development toward future human studies.
Ultra-Long-Acting Technology Powers Monthly Obesity Therapy
The ASC36_35 FDC utilizes Ascletis’ proprietary Ultra-Long-Acting Platform (ULAP) together with its Self-Assembling Lipid Depot (SALD) formulation technology, enabling sustained drug release following a once-monthly subcutaneous injection. This innovative formulation strategy is designed to improve treatment adherence while maintaining consistent therapeutic activity over extended periods. The investigational therapy represents part of Ascletis’ expanding portfolio of metabolic disease candidates developed using its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) platform and peptide engineering technologies. Beyond ASC36_35, the company continues to advance multiple obesity programs targeting GLP-1, GIP, amylin, and glucagon receptors, reflecting the industry’s growing emphasis on combination therapies capable of delivering greater metabolic benefits than single-agent approaches.
Advertisement
EASD Presentation Highlights Growing Obesity Innovation
Selection for an oral discussion at the European Association for the Study of Diabetes (EASD) Annual Meeting represents important scientific recognition for Ascletis’ obesity research program. The annual congress is internationally recognized for presenting breakthrough advances in diabetes, obesity, and metabolic disease research, bringing together leading investigators, clinicians, and pharmaceutical innovators from around the world. The presentation of ASC36_35 data alongside other emerging obesity therapies reflects increasing interest in multi-target metabolic medicines capable of addressing the complex biological mechanisms underlying chronic weight management. As global demand for more effective obesity treatments continues to rise, Ascletis’ once-monthly triple-target investigational therapy has the potential to contribute to the next generation of long-acting metabolic therapeutics aimed at improving efficacy, convenience, and long-term patient outcomes.
Source: Ascletis Pharma Press release
